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Abstract
Purpose of Review Multiple sclerosis (MS) is the most frequent neuroinflammatory disease of the central nervous system and is
commonly associated with lower urinary tract (LUT) dysfunction. As a consequence, health-related quality of life is often
impaired and the upper urinary tract might be at risk for damage. The aim of this review is to give an overview of current
treatment options for LUT dysfunction in patients with MS.
Recent Findings The treatment is tailored to the type of dysfunction—storage or voiding dysfunction—beginning with conser-
vative treatment options and ending with invasive therapies and surgery. Additionally, alternative options, e.g., different
intravesical therapies or cannabinoids, have been evaluated in recent years with promising results.
Summary Current available therapies offer different possible treatments for LUT dysfunction in patients with MS. They address
either voiding or storage dysfunction and therefore ameliorate LUT symptoms improve quality of life and protect the upper
urinary tract.
Keywords Review . Neurogenic lower urinary tract dysfunction . Neurogenic bladder treatment . Incontinence . Retention .
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Introduction
Multiple sclerosis (MS) is the most common neuroinflammatory
disease of the central nervous system and is a leading cause for
lower urinary tract (LUT) dysfunction in neurological patients.
LUT symptoms are reported on an average 8 years after the
diagnosis of MS. However, in one out of ten patients with MS,
LUT symptoms may be reported at the time of the initial MS
manifestation [1]. Due to the progressive nature of MS, preva-
lence of LUTsymptoms and dysfunction increases over time and
reaches close to 100% by 10 years [2]. LUT dysfunction has a
significant negative impact on quality of life (QoL) in patients
with MS [3] and imposes a significant burden on national health
care services in terms of resource allocation [4]. This emphasizes
the importance of neuro-urological management in this highly
complex patient population.
LUT dysfunction may present as problems of either urinary
storage or voiding. Storage (overactive bladder, OAB) symp-
toms include urinary urgency, increased daytime frequency,
nocturia (night-time frequency), and incontinence whereas
voiding symptoms include urinary hesitancy, weak and
interrupted stream, straining to urinate, double voiding, and
sensation of incomplete bladder emptying after voiding. The
pattern of symptoms and dysfunction is influenced by the
distribution of MS lesions in the neuroaxis [5, 6]. Lesions in
the subcortical white matter, brainstem, and spinal cord white
matter that affect the neural network responsible for control of
LUT functions in health result in neurogenic detrusor overac-
tivity (NDO) [7, 8]. The severity of storage symptoms corre-
late with patients’ disability measured by the Expanded
Disability Status Scale (EDSS) [6]. Moreover, a higher
EDSS is associated with unfavorable urodynamic parameters
that increase the risk for upper urinary tract damage [9••].
Detrusor external sphincter dyssynergia (DESD) leading to
an increased bladder outlet resistance, and to a lesser extent
detrusor underactivity (DU) due to impaired detrusor contrac-
tility and/or limited contraction duration, are responsible for
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voiding dysfunction, incomplete bladder emptying, and ele-
vated post-void residuals (PVR) [1, 10]. Voiding dysfunction
may be accentuated by iatrogenic factors such as treatment for
storage dysfunction with antimuscarinic agents or
intradetrusor botulinumtoxinA injections (BTX-A).
Needless to say, the chronic progressive nature of MS, its
heterogeneity and patients’ expectations, highlight the im-
portance of individually tailored treatment plans. The aim of
this review is to provide an overview of current treatment
options and recommendations for LUT dysfunction in pa-
tients with MS.
LUT Dysfunction Management
The management of LUT dysfunction focuses, primarily, on
the improvement of patients’ symptoms and QoL and, second-
arily, on the preservation of the upper urinary tract and avoid-
ance of urological complications (e.g., urinary tract infections,
bladder stones, and renal impairment). Currently, a broad ar-
mamentarium of established therapies can be offered to man-
age LUT dysfunction in MS. First-line treatments include flu-
id management, pelvic floor muscle training (PFMT), and
medical therapies (e.g., antimuscarinic agents), and second-
line treatments include BTX-A injections, intravesical thera-
pies, invasive and non-invasive neuromodulation, and cathe-
terization. Surgery may be indicated in select cases (Fig. 1).
First-line management can be initiated in neurological prac-
tice, but early referral to a urology service should be consid-
ered in certain situations (Table 1).
Conservative Management
Pelvic Floor Muscle Training
Pelvic floor muscle training may be used solely, or in com-
bination with other therapies, to treat LUT dysfunction in
patients with MS. PFMT is effective in patients who dem-
onstrate the ability to contract pelvic floor muscles. The
proposed mechanism of action is through the activation of
an inhibitory reflex on detrusor activity when the pelvic
floor muscles are voluntarily contracted [11]. The benefits
of PFMT are modest [12, 13] and studies are limited by low
patient numbers and heterogeneous outcome measures. A
recent study demonstrated that PFMT alone or in combina-
tion with neuromuscular electrical stimulation (NMES) or
transcutaneous tibial nerve stimulation (TTNS) improved
storage symptoms in women with MS [14••]. Due to its
non-invasiveness, PFMT should be continued whenever
possible throughout the treatment course.
Medical Treatments
The recommendations for pharmacological treatment of LUT
dysfunction in neurological patients depend on whether the
patient has storage (overactive bladder) or voiding (underactive
bladder or detrusor sphincter dyssynergia) problems but are
specifically selected often based on anecdotal experience, ex-
pert opinion, and extrapolation of the results from clinical trials
in non-neurological patients [4, 15–17]. For storage problems,
antimuscarinics are the first-line option, and more recently,
beta-3-receptor agonists have become available and can be use-
ful either as an add-on or stand-alone treatment.
Antimuscarinics with a beneficial neurologic side effect profile
such as darifenacin or trospium (see the “Antimuscarinics” sec-
tion) can be a good choice in patients with neurological disease
such as MS. To observe how patients might tolerate a medica-
tion, treatment should be initiated with the lowest dose, which
can subsequently be increased depending on patients’ symp-
toms and occurrence of medication-related side effects. There
is no clear consensus on how long antimuscarinics should be
given before assessing their efficacy. However, there is one
study assessing efficacy of solifenacin and tolterodine in pa-
tients with idiopathic OAB where the reported median time
for a therapeutic response was 3 months [18]. Usually, two
different antimuscarinics are trialed before the patient is consid-
ered to be refractory to medical therapy and second-line treat-
ments—including BTX-A intradetrusor injections and
neuromodulation—may be evaluated (Fig. 1).
For voiding problems, only alpha-blockers are currently
considered for medical therapy, and in refractory cases
neuromodulation or catheterization, preferably clean intermit-
tent catheterization (see the “Catheterization” section) can be
offered. However, there are no recommendations for the treat-
ment of the underlying causes DESD and DU.
Antimuscarinics
Different antimuscarinic medications are available for manag-
ing LUT symptoms, with similar efficacy and treatment out-
comes (Table 2). They reduce NDO and OAB symptoms by
blocking muscarinic receptors distributed throughout the
detrusor and suburothelium, thus blocking parasympathetic-
mediated activation of the detrusor [19]. The M3 muscarinic
receptor is of greatest significance functionally; however,
most of the antimuscarinics non-selectively bind with musca-
rinic receptors of different sub-types across several organs.
This is responsible for the side effect profile of these medica-
tions including dry mouth, blurred vision, and constipation
[20], which influence adherence to these medications [20, 21].
A recently published double-blind, randomized con-
t r o l l e d t r i a l (RCT ) c ompa r i n g two d i f f e r e n t
antimuscarinics, oxybutynin and solifenacin, to placebo
demonstrated significant improvements in urinary
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Fig. 1 Algorithm for managing
LUT dysfunction in patients with
MS. Initial evaluation includes
symptom and QoL assessment.
UTI should be excluded and
ultrasound scan KUB evaluates
the upper and lower urinary tract
and provides measure of the PVR.
If there is a significant degree of
voiding dysfunction, intermittent
catheterization should be
considered before treating the
storage dysfunction. If initial
medical treatment fails, options
such as BTX-A and
neuromodulation could be
considered. Asterisk: additional
assessment and quantification
with QoL and symptom
questionnaires; number sign: by
ultrasound scan or in-out
catheterization; degree sign:
alpha1-blockers in selected cases.
KUB kidney ureter bladder, PVR
post void residual, QoL quality of
life, UTI urinary tract infections
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frequency and incontinence, as well as QoL with both
medications. Additionally, urodynamic parameters such
as the maximum cystometric capacity also improved.
The most common reported side effect was dry mouth,
more often affecting patients using oxybutynin than
solifenacin [27••]. To avoid side effects and/or simulta-
neously improve treatment efficacy, the combination of
an antimuscarinic with mirabegron or an alpha1-blocker
(e.g., tamsulosin), particularly in men with additional
prostate-related voiding dysfunction, might be explored.
However, the current evidence of such combinations is
exclusively based on data from patients with idiopathic
LUT dysfunction [28, 29].
Meta-analyses of studies evaluating the efficacy of
antimuscarinics in neurological patients have shown no
significant differences in efficacy between individual
agents [20]. Rather, the extent of side effects is consider-
ably less among newer antimuscarinics such as solifenacin,
tolterodine, and fesoterodine and therefore these are pre-
ferred in general. The use of medications with anticholin-
ergic properties has been linked with incidental dementia
in an epidemiological study [30], linking their use with
poorer cognition, reduced cerebral glucose metabolism, in-
creased brain atrophy, and greater clinical decline [31••].
This is of particular relevance in MS where cognitive im-
pairment can affect 43–65% of patients [32, 33]. In patients
where cognitive impairment is a concern, trospium chlo-
ride is an option to consider because its quaternary amine
structure renders it relatively impermeable to the blood-
brain barrier [34, 35]. Alternatively, darifenacin may be
considered in view of its high selectivity for the M3 mus-
carinic receptors in the bladder [36].
However, despite these concerns, antimuscarinic agents
continue to be the first-line treatment for OAB in neurological
patients due to their favorable cost-benefit ratio [4].
Mirabegron
Mirabegron is a beta-3-receptor agonist and therefore works
differently from antimuscarinics. In non-neurologic pa-
tients with bladder storage dysfunction, mirabegron is asso-
ciated with significant improvements in incontinence epi-
sodes and urinary frequency [37]. However, data on effica-
cy and safety inMS are limited. Zachariou et al. demonstrat-
ed in a recently published open-label study that mirabegron
and desmopressin, either alone or in combination, signifi-
cantly improved urinary urgency, frequency, and inconti-
nence episodes [38••].
Possible side effects include hypertension, tachycardia, and
headache [37]. Despite the limited evidence base in neurogen-
ic OAB, mirabegron is increasingly being used as an alterna-
tive to or in combination with antimuscarinics.
Table 2 Currently available antimuscarinic agents for the treatment of neurogenic LUT dysfunction
Agent Release type Dose (mg) Frequency Level of evidence
for treatment of
neurogenic LUT
dysfunction
Darifenacin Controlled release 7.5–15 Once daily NA
Fesoterodine Controlled release 4–8 Once daily NA
Oxybutynin Immediate release 2.5–5 2–3 times daily 1 [22]
Controlled release 5–20 Once daily 1 [22]
Transdermal patch 36 Replace once every 3–4 days 1 [22]
Propiverine Immediate release 15 1–3 times daily 1 [23]
Controlled release 30 Once daily 1 [23]
Solifenacin Controlled release 5–10 Once daily 2 [24]
Tolterodine Immediate release 2–4 1–2 times daily 3 [25]
Controlled release 4 Once daily 3 [25]
Trospium chloride Immediate release 20 Twice daily 1 [26]
Controlled release 60 Once daily 1 [26]
NA not available
Table 1 The presence of
red flags should initiate
an early referral to
urology services
Presence of hydronephrosis
Renal impairment
Recurrent urinary tract infections
Hematuria
Suspicion of concomitant urologic
pathology (e.g., prostate enlargement),
stress urinary incontinence
Loin and/or pelvic pain
Symptoms refractory to 1st-line treatment
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Alpha1-blockers
Alpha1-adrenergic blockers exert an inhibitory effect on the
sympathetic innervation of the smooth muscle of the blad-
der neck and internal urethral sphincter, thereby reducing
the extent of bladder outlet obstruction [39•]. Data on the
efficacy and safety of alpha1-blockers to treat neurogenic
bladder dysfunction are limited [40, 41, 42•], and the only
published study, specifically in MS, demonstrated a signif-
icant improvement in voiding parameters including peak
flow rate [43]. Alpha1-blockers are a well-established
first-line treatment for male patients with voiding dysfunc-
tion due to benign prostate enlargement and can be consid-
ered as an option in men with MS reporting significant
voiding dysfunction [4, 44, 45]. Moreover, they can be com-
bined with antimuscarinics in patients with concomitant
storage symptoms (see the “Antimuscarinics” section).
Most common side effects are retrograde ejaculation and
orthostatic dysregulation, which are reversible.
Desmopressin
Desmopressin is a synthetic vasopressin (antidiuretic hor-
mone, ADH) analogue which enhances water reabsorption
in the renal collecting duct by upregulation of water channels
(aquaporin II) via V2-receptors [46]. As a result, urine volume
decreases so that patients with diabetes insipidus, nocturnal
enuresis, and nocturia can be treated.
The results from a meta-analysis of studies in MS pub-
lished in 2005 demonstrated that desmopressin reduced day-
time frequency, urine volume, and sleep efficiency by
prolonging the duration of uninterrupted sleep by an average
of 2 h. Desmopressin is effective for the treatment of nocturia
due to MS-related NDO with maximum bladder capacity be-
ing a clinically useful predictor of treatment response [47].
Desmopressin has been shown to improve urinary frequency,
urgency, incontinence episodes, and pad usage, and the effects
were accentuated when combined with mirabegron [38••].
The most common side effect is hyponatremia (8%) [48],
followed by urinary retention (0–8%) and headache (3–4%)
[49]. Patients at increased risk for hyponatremia are females,
elderly patients, and patients with concomitant cardiac disease
or elevated 24-h urine volume [50, 51]. In those patient groups,
sodium levels should be monitored periodically when using
desmopressin, especially in the initial phase [52]. A suggested
monitoring plan by Juul et al. includes baseline sodium moni-
toring, which should be ≥ 135 mmol/L, and additional moni-
toring at week 1 andmonth 1 particularly in patients at high risk
for developing hyponatremia [53]. Moreover, it is also well
known that long-term administration of desmopressin might
slowly lower sodium serum levels over time. Therefore, serum
sodium should be periodically monitored every 6 months [54].
To reduce the risk for developing hyponatremia, desmopressin
should be administered only once in 24 h, and fluid intake
should be limited during the 6–8-h period of effect.
Phosphodiesterase Type 5 Inhibitors
Phosphodiesterase type 5 inhibitors (PDE5Is) regulate smooth
muscle tone via the nitric oxide (NO) pathway and are recom-
mended as first-line on demand treatment for neurogenic erec-
tile dysfunction (ED) in patients with MS [55, 56]. However,
they have also been shown to be effective for managing OAB
[57••]. Tadalafil 5 mg daily significantly improved subjective
storage and voiding symptoms and additionally had a positive
impact on maximum flow rate and PVR in a small cohort of
20 young male MS patients, besides having a positive effect
on erectile functions [57••]; however, no studies are available
in women. In general, PDE5Is are a promising option for
managing MS-related urogenital dysfunction, although rec-
ommendations for its use currently do not exist.
Cannabinoids
Cannabinoid receptors play a significant role in sensory
nerve signaling, bladder afferent functions, and possibly
modulation of cholinergic nerves [58]. Cannabinoid prepa-
rations reduce detrusor contractility possibly through can-
nabinoid receptors [59, 60] distributed in the detrusor and
the central nervous system [61]. Recreational use of inhaled
cannabis has been shown to improve LUT symptoms in MS
[62]. In a recent systematic review, efficacy and safety of
cannabinoids for the treatment of LUT dysfunction in pa-
tients with MS was evaluated. Despite the low quality of
existing evidence due to heterogeneity in reported out-
comes, small numbers of patients studied, and insufficient
follow-up, the evidence suggests that treating LUT dysfunc-
tion might be effective with a favorable safety profile [63••].
However, cannabinoids are currently not licensed for
treating LUT dysfunction, are illegal in the USA according
to federal law, and not reimbursed in several countries.
Intravesical Treatments
BotulinumtoxinA
Ona b o t u l i n um t o x i nA (Bo t o x , A l l e r g a n ) a n d
abobotulinumtoxinA (Dysport, Ipsen Biopharm Ltd.) are used
for the treatment of NDO. A comparative study between these
molecules is lacking, though outcomes appear to be similar
when used in animal models [64].
Intradetrusor onabotulinumtoxinA has become a well-
established second-line treatment for NDO. Injections are
administered via cystoscopy under local or general anesthe-
sia. Two pivotal phase 3 studies reported that 200 and
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300 IU onabotulinumtoxinA significantly reduces urinary
incontinence episodes and improves QoL and urodynamic
parameters in patients with MS and spinal cord injury (SCI)
[65, 66]. Clinically significant benefits were observed after
6 weeks and 60% of patients reported a significant reduction
in weekly urinary incontinence episodes and improvement
of QoL using both dosages compared to placebo. Botulinum
toxin inhibits detrusor activity and thereby is associated
with developing urinary retention. De novo initiation of
clean intermittent catheterization (CIC) was significantly
different between the two groups, i.e., 30 versus 42% in
the 200 and 300 IU groups, respectively, compared to 12%
in the placebo group [65]. However, there were no signifi-
cant differences in efficacy or duration of effect between the
two dosages. Moreover, both dosages were well tolerated
with a more favorable safety profile, i.e., UTI rate, in the
200 IU group. For these reasons, 200 IU onabotulinumtoxinA
was approved by the US Food and Drug Administration (FDA)
in 2011 for treating NDO and is licensed in Europe for the
treatment of NDO in MS and SCI. Most frequent reported
adverse events after onabotulinumtoxinA intradetrusor injec-
tions include urinary retention and UTIs in 52 and 56%, respec-
tively [67]. OnabotulinumtoxinA has proven efficacy over
long-term repeat injections [68••] with consistent inter-
injection intervals [69]. However, discontinuation of treatment
is a relevant issue and Leitner et al. showed in a consecutive
series of patients with LUT dysfunction due to different neuro-
logical conditions with a follow-up of up to 17 years that ap-
proximately 40% of patients discontinue treatment over time.
Reasons for discontinuation were lack of clinical and/or
urodynamic effects, or preference of another treatment such as
neuromodulation or bladder augmentation despite objective ev-
idence for efficacy. More than half of patients in the MS sub-
group discontinued treatment due to progression of MS and
progressive loss of responsiveness to botulinumtoxinA (BTX-
A) [70••].
In a retrospective study with a mixed group of neurological
patients with refractory LUT dysfunction using intradetrusor
injections of 750 IU abobotulinumtoxinA, 64% of patients
reported significantly improved continence rates after 6 weeks
and a reduction in mean maximum detrusor pressures compa-
rable to after onabotulinumtoxinA use. The study confirmed
long-time safety and efficacy of abobotulinumtoxinA 750 IU
over a mean follow-up of 28 months [71••].
Other Intravesical Treatments
Intravesical administration of active pharmaceutical ingredi-
ents might be considered to avoid systemic side effects be-
cause of different metabolic pathways [72]. In a recently pub-
lished systematic review on intravesical administration of
vanilloids (capsaicin and resiniferatoxin) in MS, intravesical
vanilloid instillation was shown to be effective for treating
LUT dysfunction. However, the safety profile was unfavor-
able with reports of pelvic pain, urinary tract infection, and
hematuria reported by > 50% of the patients [73]. Therefore,
no current high-quality evidence has been published to sup-
port the use of vanilloids for intravesical therapy in patients
with MS. Moreover, clinical studies have shown that
resiniferatoxin has limited clinical efficacy compared to
BTX-A injections in the detrusor [74].
Studies have evaluated intravesical administration of
antimuscarinic agents and shown that the use of intravesical
oxybutynin is efficacious and safe [75•, 76, 77]. There is no
general consensus on cumulative dose and administration fre-
quency. Schroder et al. used a protocol with intravesical ad-
ministration of 10mL oxybutynin hydrochloride 0.1% (10 mg
oxybutynin hydrochloride/10 mL 0.9% saline) three times
daily (cumulative dose 30 mg/day) directly into an emptied
bladder through a urethral catheter [75•].
Since all currently existing studies evaluate intravesical
oxybutynin only in patients with SCI or spina bifida, rec-
ommendations for its use in MS cannot be made. However,
since any intravesical administration requires catheteriza-
tion, acceptance of this form of therapy might be greater in
patients already performing CIC than in patients spontane-
ously voiding [77].
Neuromodulation
Tibial Nerve Stimulation
Percutaneous and transcutaneous tibial nerve stimulation
(PTNS and TTNS, respectively) have been shown to be ben-
eficial in the management of OAB. Stimulation is performed
by introducing a needle electrode (PTNS) or cutaneous patch
electrode (TTNS) over the course of the tibial nerve, approx-
imately 5 cm cephalad and posterior to the medial malleolus.
The treatment schedule conventionally adopted is intermittent
30 -min stimulation sessions over 12 sessions. There is no
evidence favoring one schedule over the other [78].
Schneider et al. assessed efficacy and safety of both treatments
in a systematic review with meta-analysis [79••]. The results
were promising and showed that PTNS and TTNS might be
effective and safe for the treatment of neurogenic LUT dys-
function. However, the quality of included studies was low,
with only a few studies evaluating patients with MS.
TTNS has been shown to be an effective treatment. In a
prospective open-label study, de Sèze et al. demonstrated
through a pre-post treatment design that urgency, leakages,
QoL, and urodynamic parameters significantly improved after
daily TTNS treatment for 3 months [80]. Additionally, Kabay
et al. reported that a durable effect could be achieved with a
tapering protocol over 12 months in treatment responders
[81••]. The effects of tibial nerve stimulation are comparable
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to antimuscarinic agents in the non-neurological population
[82]; however, how this treatment compares with BTX-A
has never been evaluated.
Sacral Neuromodulation
In contrast to tibial nerve stimulation, sacral neuromodulation
(SNM) is a surgical treatment implanting a stimulation elec-
trode in the sacral foramen S3 connected to a battery device,
which is usually placed in the upper buttock [83].
In a systematic review by Kessler et al. assessing efficacy of
SNM in neurogenic patients, subgroup analysis of patients with
MS showed a success rate of 84%, defined as an improvement of
> 50% in different variables such as number of leakages, pad
use, number of voids, and number of catheterizations using a
bladder diary [84, 85]. Overall evidence indicates that SNM
may be effective and safe in patients with LUT dysfunction.
However, the conclusion is limited due to small number of pa-
tients studied and low quality and heterogeneous study designs
[86]. The success rate is consistent with an earlier published
retrospective cohort study, which reported significant reductions
in day and night-time frequency, incontinence episodes, pad us-
age, and number of CICs per 24 h in a mixed neurological
patient group with almost 50% of patients having MS [87].
However, in view of the progressive course of neurological
and urological disability, the benefits of SNMmay be lost over
time [70••]. Moreover, according to the manufacturer, the cur-
rently available device InterStim II (Medtronic, Inc.,
Minneapolis, MN, USA) is MR incompatible, and therefore,
using this device would not be an option in patients requiring
repeat magnetic resonance (MR) imaging. Elkelini and
Hassouna, however, have reported a series of eight patients
with implanted SNM undergoing MR imaging at 1.5 Tesla
without safety concerns [88].
In conclusion, there is evidence suggesting effectivity of
SNM for treating LUT dysfunction but due to the lack of
well-designed RCTs, no final recommendations can be made.
A double-blind RCT in patients with LUT dysfunction due to
different neurological conditions (ClinicalTrials.gov
NCT02165774) is however underway [89].
Surgical Options
In select MS patients with LUT dysfunction refractory to first-
and second-line treatments, surgery might need to be consid-
ered as an option. The risk for developing upper urinary tract
damage is low compared to other neurological conditions such
as SCI, and the consideration for surgery has further declined
over the years in view of the availability of effective first- and
second-line treatments. The role for surgery in the manage-
ment ofMS-related LUT dysfunction is therefore limited [90].
Surgery might be a valuable option particularly in young
individuals with anticipated long-life expectancy and patients
with substantial impairment in QoL due to refractory LUT
dysfunction. Surgical options that might be offered include
bladder augmentation, cystectomy, and continent and inconti-
nent urinary diversion. The choice of surgery is influenced to a
large extent by motor functions and cognitive abilities, and
patient expectations. However, as MS is a progressive disease
with likely deterioration of these neurological disabilities and
inability to catheterize over time, an incontinent urinary diver-
sion such as an ileal conduit is often preferred [91].
A prospective study evaluating MS patients with advanced
disease showed that laparoscopic-assisted cystectomy with
ileal conduit was associated with significant improvement in
QoL domains such as limitations, constraints, and specific
urinary impact index using the Qualiveen questionnaire,
though the overall score remained unchanged. A higher com-
plication rate was reported in patients with longer disease
duration, suggesting that surgical management should be con-
sidered as a possibility early in patients refractory to first- and
second-line treatments who are likely to progress [92].
Women with pelvic floor insufficiency reporting stress uri-
nary incontinence (SUI) may be offered a mid-urethral sling in
select cases; however, they should undergo cystoscopy and
urodynamic study to assess the risk of developing urinary
retention post-operatively [90].
Catheterization
Depending on the pattern and extent of LUT dysfunction
and patients’ disability level, intermittent or indwelling
catheterization may be offered to address the problem of
incomplete bladder emptying. Most MS patients present
with storage dysfunction [2]; however, voiding dysfunction
and urinary retention occur in up to 70% [93]. Moreover,
managing storage dysfunction with antimuscarinics or
intradetrusor BTX-A injections is often associated with
worsening voiding.
Since the introduction of clean intermittent catheterization
(CIC) in a patient with MS by Lapides et al. in 1972, CIC has
become the gold standard in the treatment of voiding dysfunc-
tion [94]. One prospective cohort study demonstrated a sig-
nificant impact in bladder-specific QoL using the Qualiveen
questionnaire in patients with MS reporting LUT dysfunction
[95]. A substantial improvement in QoL and LUT symptoms
of urinary frequency, urgency, stress, and urgency inconti-
nence were reported in a cross-sectional study [96].
Additionally, regular CIC appears to improve PVR over time
inMS patients who are voiding spontaneously, suggesting that
regular complete bladder emptying avoiding overdistension
might improve bladder functions [97].
The risk of developing UTIs is a concern; however, com-
pared to other bladder-emptying methods including the use of
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indwelling transurethral or suprapubic catheters, Crédé ma-
neuver, and reflex micturition, CIC has been reported to de-
crease long-term urinary tract complications and improve
QoL in patients with neurogenic LUT dysfunction [98, 99].
In regard to patients with MS, Luoto et al. reported a higher
incidence of UTIs after initiation of CIC; however, this did not
reach statistical significance. Moreover, infections were asso-
ciated with less subjective discomfort compared to before
commencing catheterization [96]. Additionally, Andretta et
al. reported serious complications in 2 out of 10 patients with
MS (20%): one male patient developed epididymorchitis and
another patient was found to have a bladder stone [100].
As mentioned above, compared to intermittent catheteriza-
tion, indwelling catheters are associated with a greater risk for
complications such as UTIs, genital erosions, and stone for-
mation. Should long-term indwelling catheterization be con-
sidered, the suprapubic route is preferable in view of patient
comfort, facilitation of intimacy, easier handling, and lesser
complications. In the context of long-term indwelling cathe-
terization, silicone rather than latex catheters should be used as
they are associated with less susceptibility for encrustation
and allergy in the neurological population [101].
In conclusion, CIC is preferred over indwelling catheteri-
zation (grade A recommendation) as a standard treatment for
patients with LUT dysfunction who are unable to empty their
bladder despite the low level of evidence (LOE 3) [4]. There
are no specific recommendations for patients with MS.
Conclusions
Neurogenic lower urinary tract dysfunction is common in pa-
tients with MS and is associated with a significant negative
impact on quality of life. The management of bladder dys-
function is individually tailored according to the pattern of
LUT dysfunction, extent of neurological disabilities, disease
course, and patient expectations. Treatment remains a chal-
lenge for health care providers; however, adopting a treatment
algorithm beginning with non-invasive therapy offers a wide
spectrum of different treatments targeting different mecha-
nisms for managing LUT dysfunction.
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